<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080677</url>
  </required_header>
  <id_info>
    <org_study_id>SU-02112010-4963</org_study_id>
    <secondary_id>7011</secondary_id>
    <nct_id>NCT01080677</nct_id>
  </id_info>
  <brief_title>Caffeine/Propranolol Intervention for Acute Migraine</brief_title>
  <official_title>Randomized Double-Blind Study to Evaluate the Dose-Related Efficacy and Safety of Caffeine/Propranolol in the Treatment of Acute Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to assess the safety of caffeine/propranolol at different dose&#xD;
      levels. We want to find out what effects, good and/or bad, it has on patients and their&#xD;
      migraines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a screening exam to find out if potential subjects are eligible to be in the&#xD;
      main part of the study. Screening will include obtaining demographics, migraine history,&#xD;
      migraine characteristics, verification that subjects's migraine satisfies the International&#xD;
      Headache Society criteria, migraine medication history with success and failure rates, and&#xD;
      medical history.&#xD;
&#xD;
      If a subject is female, we will need to confirm to the extent medically possible that they&#xD;
      are not pregnant. Female subjects must agree to have a urine pregnancy test done before&#xD;
      beginning this research study. If a subject is a woman who is able to become pregnant, it is&#xD;
      expected that they will use an effective method of birth control to prevent exposing a fetus&#xD;
      to a potentially dangerous agent with unknown risk. They must accept the risk that pregnancy&#xD;
      could still result despite the responsible use of reliable method of birth control.&#xD;
&#xD;
      They agree to notify Dr. Cho as soon as possible of any failure of proper use of your birth&#xD;
      control method, or if you become pregnant, either of which may result in your being withdrawn&#xD;
      from the study.&#xD;
&#xD;
      Subjects will also undergo a liver function test as well as an EKG to make sure they are&#xD;
      eligible for the study.&#xD;
&#xD;
      Once subject eligibility has been determined, they will be randomized to one of 3 study&#xD;
      groups described below. Neither the subjects nor the doctor can choose which group subjects&#xD;
      will be in nor will subjects or their doctor know which group subjects are in. They will have&#xD;
      a one in three chance of being placed in any group. Two groups will be active treatment with&#xD;
      either 400 mg caffeine and 40 mg propranolol or 1000 mg caffeine and 40 mg propranolol. The&#xD;
      third group will be a placebo group with no active medication.&#xD;
&#xD;
      Subjects will then be given a study kit, which includes caffeine/propranolol or placebo oral&#xD;
      medication, a treatment booklet, migraine headache diary, pen and stopwatch. The study&#xD;
      coordinator will then instruct them in the accurate method of diary completion and use of the&#xD;
      oral medication or placebo pill. Their final visit will be scheduled within 60 days of&#xD;
      enrollment.&#xD;
&#xD;
      They will be instructed to treat one moderate or severe migraine attack with the study&#xD;
      medication. They will be instructed to take study medication at aura onset in the presence of&#xD;
      another adult.&#xD;
&#xD;
      In the absence of any aura, they will be instructed to take study medication at headache&#xD;
      onset. Another adult should be present when taking the study medication to ensure safety. In&#xD;
      the event that the migraine occurs while they are alone, the subjects are instructed not to&#xD;
      take the study medication and to wait for the next headache when adult supervision is&#xD;
      available. They will not be allowed to use any non-steroidal,anti-inflammatory drugs such as&#xD;
      ibuprofen or naproxen sodium, non-prescription analgesics such as acetaminophen or aspirin,&#xD;
      narcotic analgesics such as oxycontin, oxycodone, triptan or ergotamine medication or&#xD;
      derivatives (Cafergot®, D.H.E., 45®[dihydroergotamine mesylate], Efcaf®, Ergomar®, Ergostat®,&#xD;
      Migranal®, Nasal Spray, Sansert®[methysergide], or Wigraine®) within 24 hours prior to dosing&#xD;
      with the study medication. Subjects will also be instructed not to use any caffeine such as&#xD;
      coffee, tea, caffeine containing sodas, or caffeine containing medications (Cafcit®,&#xD;
      Caffedrine®, Enerjets, Lucidex, No Doz® Maximum Strength, Vivarin®) within 6 hours prior to&#xD;
      dosing with the study medication.&#xD;
&#xD;
      Subjects will record the severity of their headache and associated symptoms at baseline and&#xD;
      15, 30, 45, 60, and 120 minutes after dosing. If the migraine does not resolve or worsens&#xD;
      after 2 hours, they will be allowed to take #rescue medication# as prescribed by their&#xD;
      physician. Subjects will continue to record the severity of their headache and associated&#xD;
      symptoms for 4, 12, and 24 hours after initial dosing. Following the last entry in the&#xD;
      subject diary at 24 hours, they will be asked to complete a treatment satisfaction&#xD;
      questionnaire. They will also be asked to contact Dr. Cho#s office to review their diary&#xD;
      completion and to confirm the date of their final visit.&#xD;
&#xD;
      If subjects have not called to report a migraine within a month (±7 days) of enrollment, Dr.&#xD;
      Cho or someone from his research staff will call them to determine if they have treated a&#xD;
      migraine. If a migraine was treated, Dr. Cho or the study staff will interview them to&#xD;
      determine if the diary has been appropriately completed and to ensure that adequate&#xD;
      information has been recorded. Their final visit will be confirmed and should occur within 30&#xD;
      days of the treated migraine. If they have not treated a migraine with the study medication&#xD;
      within the first 30 days of enrollment, their final visit will be rescheduled within 60 days&#xD;
      of your enrollment date (± 7 days).&#xD;
&#xD;
      At the final visit, the study coordinator will review their subject diary for completeness&#xD;
      and accuracy. All study materials will need to be returned at this visit. Subjects will then&#xD;
      have a second EKG to make sure the medication didn't have any negative effects on their&#xD;
      cardiac function. Subjects will be given a voucher to pay for parking expenses. In addition,&#xD;
      there will be a data safety monitoring unblinding event after the first 15 patients have&#xD;
      completed the study. All serious and non-serious adverse events will be analyzed regardless&#xD;
      of the investigators' assessments of causality. Adverse events that result in death,&#xD;
      hospitalization, permanent disability or threat to life are classified as serious. The&#xD;
      Medical Dictionary of Regulatory Activities (MedDRA) will be used to categorize reported&#xD;
      adverse events. Someone who is not directly related to the research team will conduct the&#xD;
      safety monitoring.&#xD;
&#xD;
      If there are any serious adverse events during the study, the study will be discontinued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe or Moderate Headache Pain at Baseline to Mild or no Pain at 2 Hrs)</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Pain Free at 2 Hrs Post First Administration of Caffeine/Propranolol</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing at Least One Adverse Event of Interest</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse events may have included abdominal pain, flushing, dizziness, insomnia, or anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Satisfaction</measure>
    <time_frame>24 hours</time_frame>
    <description>Following up to 24 hours after treatment, participants were asked to report whether they were satisfied with level of pain relief provided by treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match caffeine/propranolol (single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive caffeine/propranolol 400/40 mg combination tablet (single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive caffeine/propranolol 1000/40 mg combination tablet (single dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine/propranolol combination tablet</intervention_name>
    <description>caffeine/propranolol combination tablet administered orally once daily</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to match caffeine/propranolol combination tablet administered orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1. Subject has a minimum 12-month migraine history that the investigator&#xD;
        determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for&#xD;
        migraine with or without aura 2. Subject is between 18-50 years of age. 3. Subject&#xD;
        experiences an average of 2-8 migraines per month. 4. If on preventive migraine therapy,&#xD;
        medication regimen has been stable for 30 days and will remain stable for the duration of&#xD;
        participation.&#xD;
&#xD;
        5. Subject is able to communicate adequately and comply with the requirements of the study&#xD;
        as determined by the investigator.&#xD;
&#xD;
        6. Subject is able to read and understand the informed consent written in English and&#xD;
        voluntarily consents to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:1. Subject#s age of migraine onset is greater than 50 years. 2. Subject&#xD;
        has more than 6 non-migraine headache days per month. 3. Subject has less than 48 hours of&#xD;
        freedom from headache between attacks of migraine.&#xD;
&#xD;
        4. Subject meets the criteria for complicated and/or brainstem migraines. 5. Subject is&#xD;
        pregnant or lactating. 6. Subject has history of alcohol or drug abuse within the past 2&#xD;
        years. 7. Subject has existing systolic blood pressure &lt; 100mm Hg, existing systolic blood&#xD;
        pressure &gt; 150mm Hg, and or heart rate &lt;50 beats per minute.&#xD;
&#xD;
        8. Subject has heart block greater than 1st degree without a functioning pacemaker 9.&#xD;
        Subject has a history of tachyarrythmias 10. Subject has uncompensated congestive heart&#xD;
        failure (CHF) 11. Subject has severe chronic obstructive pulmonary disease or severe&#xD;
        asthma. 12. Subject has consumed caffeine within 6 hours. 13. Subjects with existing&#xD;
        generalized anxiety disorder (GAD) and/or panic disorder.&#xD;
&#xD;
        14. Subjects with existing severe hepatic and/or renal insufficiency. 15. Subjects with&#xD;
        existing Raynaud#s disease. 16. Subject is participating in another clinical trial during&#xD;
        or within 30 days prior to study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Charles Cho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <results_first_submitted>January 28, 2015</results_first_submitted>
  <results_first_submitted_qc>January 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2017</results_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>S. Charles Cho</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo to match caffeine/propranolol (single dose)</description>
        </group>
        <group group_id="P2">
          <title>Low Dose</title>
          <description>Participants received caffeine/propranolol 400/40 mg combination tablet (single dose)</description>
        </group>
        <group group_id="P3">
          <title>High Dose</title>
          <description>Participants received caffeine/propranolol 1000/40 mg combination tablet (single dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Thirty females, thirty males, agews ranged from 18-50 years old. All had an established history of migraines for at least 1 year. All met the diagnostic criteria of the International Classification of Headache Disorders.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo to match caffeine/propranolol (single dose)</description>
        </group>
        <group group_id="B2">
          <title>Low Dose</title>
          <description>Participants received caffeine/propranolol 400/40 mg combination tablet (single dose)</description>
        </group>
        <group group_id="B3">
          <title>High Dose</title>
          <description>Participants received caffeine/propranolol 1000/40 mg combination tablet (single dose)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe or Moderate Headache Pain at Baseline to Mild or no Pain at 2 Hrs)</title>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to match caffeine/propranolol (single dose)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Participants received caffeine/propranolol 400/40 mg combination tablet (single dose)</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>Participants received caffeine/propranolol 1000/40 mg combination tablet (single dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe or Moderate Headache Pain at Baseline to Mild or no Pain at 2 Hrs)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Pain Free at 2 Hrs Post First Administration of Caffeine/Propranolol</title>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to match caffeine/propranolol (single dose)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Participants received caffeine/propranolol 400/40 mg combination tablet (single dose)</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>Participants received caffeine/propranolol 1000/40 mg combination tablet (single dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Pain Free at 2 Hrs Post First Administration of Caffeine/Propranolol</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing at Least One Adverse Event of Interest</title>
        <description>Adverse events may have included abdominal pain, flushing, dizziness, insomnia, or anxiety</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to match caffeine/propranolol (single dose)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Participants received caffeine/propranolol 400/40 mg combination tablet (single dose)</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>Participants received caffeine/propranolol 1000/40 mg combination tablet (single dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing at Least One Adverse Event of Interest</title>
          <description>Adverse events may have included abdominal pain, flushing, dizziness, insomnia, or anxiety</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Satisfaction</title>
        <description>Following up to 24 hours after treatment, participants were asked to report whether they were satisfied with level of pain relief provided by treatment</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo to match caffeine/propranolol (single dose)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Participants received caffeine/propranolol 400/40 mg combination tablet (single dose)</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>Participants received caffeine/propranolol 1000/40 mg combination tablet (single dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Satisfaction</title>
          <description>Following up to 24 hours after treatment, participants were asked to report whether they were satisfied with level of pain relief provided by treatment</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo to match caffeine/propranolol (single dose)</description>
        </group>
        <group group_id="E2">
          <title>Low Dose</title>
          <description>Participants received caffeine/propranolol 400/40 mg combination tablet (single dose)</description>
        </group>
        <group group_id="E3">
          <title>High Dose</title>
          <description>Participants received caffeine/propranolol 1000/40 mg combination tablet (single dose)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor of Neurology</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-723-5184</phone>
      <email>chos@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

